金乌骨通胶囊联合塞来昔布胶囊治疗强直性脊柱炎的临床研究

Clinical Study of Jinwugutong Capsule Combined with Celecoxib Capsule in the Treatment of Ankylosing Spondylitis

目的:观察金乌骨通胶囊联合塞来昔布胶囊治疗强直性脊柱炎(AS)的临床疗效。方法:选取天津中医药大学第一附属医院2017年4月~2020年4月期间收治的126例AS患者。采用双色球法(红色、绿色)将患者分为对照组(红色)和研究组(绿色),各63例。对照组接受塞来昔布胶囊治疗,研究组接受金乌骨通胶囊联合塞来昔布胶囊治疗,两组均治疗3个月。治疗3个月后,观察两组疗效,记录治疗期间不良反应发生率,对比两组治疗前、治疗3个月后的临床症状缓解情况、生存质量及实验室指标变化。结果:研究组的临床总有效率高于对照组(P<0.05)。治疗3个月后,研究组巴氏强直性脊柱炎疾病活动指数(BASDAI)、巴氏强直性脊柱炎功能指数(BASFI)评分低于对照组,枕墙距小于对照组,腰椎活动度、胸廓活动度大于对照组(P<0.05)。治疗3个月后,研究组世界卫生组织生存质量简表(WHOQOL-BRIEF)各维度评分高于对照组(P<0.05)。治疗3个月后,研究组血沉(ESR)、C-反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)低于对照组(P<0.05)。两组不良反应发生率组间比较无统计学差异(P>0.05)。结论:金乌骨通胶囊联合塞来昔布胶囊治疗AS患者,可促进其临床症状及生存质量改善,降低ESR及炎性因子水平,是一种安全有效的治疗方案。

Objective:To observe the clinical efficacy of Jinwugutong capsule combined with celecoxib capsule in the treatment of ankylosing spondylitis(AS).Methods:126 patients with AS who were treated in The First Affiliated Hospital of Tianjin University of traditional Chinese Medicine from April 2017 to April 2020 were selected.The patients were divided into control group(red)and study group(green)by two-color ball method(red and green),63 cases in each group.The control group was treated with celecoxib capsule,and the study group was treated with Jinwugutong capsule combined with celecoxib capsule.Both groups were treated for 3 months.3months after treatment,the curative effect of the two groups was observed,the incidence of adverse reactions during the treatment was recorded,and the clinical symptom relief,quality of life and laboratory index changes of the two groups before and 3 months after treatment were compared.Results:The total effective rate of the study group was higher than that of the control group(P<0.05).3 months after treatment,the scores of disease activity index of pasteurized ankylosing spondylitis(BASDAI),barthel Ankylosing Spondylitis Functional Index(BASFI)of the study group were lower than those of the control group,the occipital wall distance was less than that of the control group,and the lumbar mobility and thoracic mobility were greate than those of the control group(P<0.05).3 months after treatment,the scores of WHO quality of life brief(WHOQOL-BRIEF)each dimension of the study group were higher than those of the control group(P<0.05).3 months after treatment,erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)of the study group were lower than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Jinwugutong capsule combined with celecoxib capsule in the treatment of patients with AS can promote the improvement of clinical symptoms and quality of life,and reduce the levels of ESR and inflammatory factors,which is a safe and effective treatment plan.